Vistagen Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Vistagen Therapeutics, Inc. (VTGN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Operating Activities
Net Income-51.42-29.36-59.25-47.76-17.93-20.77-24.59
Depreciation & Amortization0.640.570.530.710.480.540.09
Stock Based Compensation4.322.183.343.482.310.000.00
Change in Working Capital4.760.792.46-2.253.390.091.72
Change in Accounts Payable5.680.52-0.931.690.050.000.00
Change in Other Working Capital-0.92-0.252.76-2.60-0.640.000.00
Other Operating Activities-0.391.696.543.041.994.384.78
Net Cash from Operating Activities-42.10-25.81-49.72-45.26-12.07-15.76-14.53
Investing Activities
Capital Expenditures-0.19-0.060.530.200.280.00-0.17
Acquisitions0.000.00-0.530.000.000.000.00
Purchases of Investments-24.980.000.000.000.000.000.00
Sales/Maturities of Investments12.03-0.06-0.21-0.200.000.000.00
Other Investing Activities0.00-0.06-0.21-0.200.000.000.00
Net Cash from Investing Activities-13.15-0.06-0.74-0.20-0.280.00-0.17
Financing Activities
Debt Repayment0.00-0.99-1.030.00-0.61-0.30-0.22
Common Stock Issued3.01129.380.1710.4915.803.6017.04
Common Stock Repurchased0.000.00-0.170.000.000.000.00
Other Financing Activities0.200.00-0.175.956.360.000.00
Net Cash from Financing Activities3.21128.40-1.0410.48114.104.0117.42
Summary
Net Change in Cash-52.04102.53-51.50-34.97101.75-11.752.72
Cash at Beginning of Period119.1716.6468.14103.111.3613.1010.38
Cash at End of Period67.13119.1716.6468.141.361.3613.10
Free Cash Flow-42.29-25.87-50.24-45.26-12.35-15.76-14.70
Supplemental Disclosures
Interest Paid0.000.000.000.000.010.010.01
Income Taxes Paid0.000.000.000.000.000.000.00